|
Characteristic
|
All patients [cases (%)]
|
|---|
|
Total
|
2660
|
|
Age
|
|
≤ 50 years
|
564 (21.2)
|
|
51–64 years
|
1031 (38.8)
|
|
≥ 65 years
|
1065 (40.0)
|
|
Race
|
|
White
|
2169 (81.5)
|
|
African American
|
351 (13.2)
|
|
Others
|
140 (5.3)
|
|
Sex
|
|
Female
|
2607 (98.0)
|
|
Male
|
53 (2.0)
|
|
Charlson–Deyo comorbidity score
|
|
0
|
2210 (83.1)
|
|
1
|
362 (13.6)
|
|
≥ 2
|
88 (3.3)
|
|
Clinical T stage
|
|
T1
|
1655 (62.2)
|
|
T2
|
738 (27.7)
|
|
T3
|
184 (6.9)
|
|
T4
|
83 (3.1)
|
|
Clinical N stage
|
|
N0
|
1998 (75.1)
|
|
N1
|
532 (20.0)
|
|
N2
|
81 (3.0)
|
|
N3
|
49 (1.8)
|
|
Surgery
|
|
Lumpectomy
|
1281 (48.2)
|
|
Mastectomy
|
1379 (51.8)
|
|
Lymph nodes involved
|
|
0
|
1243 (46.7)
|
|
1–3
|
689 (25.9)
|
|
≥ 4
|
501 (18.8)
|
|
Unknown
|
227 (8.5)
|
|
Histologic gradea
|
|
1
|
196 (7.4)
|
|
2
|
1333 (50.1)
|
|
3
|
971 (36.5)
|
|
Not reported
|
160 (6.0)
|
|
ER status
|
|
Positive
|
2327 (87.5)
|
|
Negative
|
291 (10.9)
|
|
Unknown
|
42 (1.6)
|
|
PR status
|
|
Positive
|
2112 (79.4)
|
|
Negative
|
498 (18.7)
|
|
Unknown
|
50 (1.9)
|
|
HER2 status
|
|
Positive
|
397 (14.9)
|
|
Negative
|
1498 (56.3)
|
|
Unknown
|
765 (28.8)
|
|
Tumor markers
|
|
ER+ HER2−
|
1402 (52.7)
|
|
ER+ HER2+
|
297 (11.2)
|
|
ER− HER2+
|
99 (3.7)
|
|
ER− HER2−
|
95 (3.6)
|
|
Not reported
|
767 (28.8)
|
|
Radiotherapy
|
|
Yes
|
1592 (59.8)
|
|
No
|
1068 (40.2)
|
|
Chemotherapy
|
|
Yes
|
1273 (47.9)
|
|
No
|
1024 (38.5)
|
|
Not reported
|
363 (13.6)
|
|
Hormonal therapy
|
|
Yes
|
1979 (74.4)
|
|
No
|
501 (18.8)
|
|
Not reported
|
180 (6.8)
|
- ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
- aWell, moderately, and poorly differentiated/undifferentiated tumors were classified into histologic grades 1, 2, and 3, respectively
